ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
2seventy bio Inc

2seventy bio Inc (TSVT)

2.66
0.04
(1.53%)
마감 01 2월 6:00AM
2.67
0.01
(0.38%)
시간외 거래: 9:59AM

행사 가격매수가매도가최근 가격중간 가격가격 변동가격 변동 %거래량미결제 약정최근 거래
2.500.104.100.102.100.000.00 %020-
5.000.000.000.000.000.000.00 %00-

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

행사 가격매수가매도가최근 가격중간 가격가격 변동가격 변동 %거래량미결제 약정최근 거래
2.500.050.300.100.1750.000.00 %019-
5.002.052.800.002.4250.000.00 %00-

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
729.72M
REBNReborn Coffee Inc
US$ 3.31
(63.05%)
55.54M
FCUVFocus Universal Inc
US$ 5.87
(56.62%)
1.73M
SOPASociety Pass Inc
US$ 1.54
(56.50%)
13.82M
CYCNCyclerion Therapeutics Inc
US$ 3.92
(54.33%)
82.39M
ENVBEnveric Biosciences Inc
US$ 2.0899
(-46.41%)
1.58M
NIVFNewGenIvf Group Ltd
US$ 0.1489
(-42.51%)
14.91M
GLSTGlobal Star Acquisition Inc
US$ 8.83
(-39.10%)
23.93k
PRPHProPhase Labs Inc
US$ 0.2633
(-38.02%)
900.48k
SPGCSacks Parente Golf Inc
US$ 0.5601
(-37.86%)
7.42M
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
731.1M
NVDANVIDIA Corporation
US$ 120.07
(-3.67%)
388.5M
RIMEAlgorhythm Holdings Inc
US$ 0.02565
(5.12%)
341.8M
CLEUChina Liberal Education Holdings Ltd
US$ 0.1938
(30.77%)
237.15M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0355
(-11.25%)
236.44M

TSVT Discussion

게시물 보기
Monksdream Monksdream 5 월 전
TSVT under $5
👍️0
Monksdream Monksdream 9 월 전
TSVT under $5
👍️0
Invest-in-America Invest-in-America 11 월 전
TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
👍️0
Monksdream Monksdream 11 월 전
TSVT 10Q due March 5
👍️0
molee molee 1 년 전
$TSVT > A bit of "short covering" going on now ... How high ???
👍️0
Monksdream Monksdream 1 년 전
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👎️ 1
johnhancoque johnhancoque 1 년 전
2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.
👍️0
molee molee 1 년 전
C'mon man . What the heck . $2.00 now ? Really ?
👍️0

최근 히스토리

Delayed Upgrade Clock